These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9124185)

  • 1. The role of radionuclide angiocardiography in the treatment of patients receiving doxorubicin-based chemotherapy: a reassessment.
    Dreicer R; Karwal MW; Midence G; Davis CS; Nettleman M
    Am J Clin Oncol; 1997 Apr; 20(2):132-7. PubMed ID: 9124185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.
    Choi BW; Berger HJ; Schwartz PE; Alexander J; Wackers FJ; Gottschalk A; Zaret BL
    Am Heart J; 1983 Oct; 106(4 Pt 1):638-43. PubMed ID: 6613807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
    Schwartz RG; McKenzie WB; Alexander J; Sager P; D'Souza A; Manatunga A; Schwartz PE; Berger HJ; Setaro J; Surkin L
    Am J Med; 1987 Jun; 82(6):1109-18. PubMed ID: 3605130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography.
    Suzuki J; Yanagisawa A; Shigeyama T; Tsubota J; Yasumura T; Shimoyama K; Ishikawa K
    Angiology; 1999 Jan; 50(1):37-45. PubMed ID: 9924887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas.
    Dresdale A; Bonow RO; Wesley R; Palmeri ST; Barr L; Mathison D; D'Angelo T; Rosenberg SA
    Cancer; 1983 Jul; 52(1):51-60. PubMed ID: 6850545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
    Villani F; Meazza R; Materazzo C
    Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
    Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
    Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.
    Blaes AH; Rehman A; Vock DM; Luo X; Menge M; Yee D; Missov E; Duprez D
    Vasc Health Risk Manag; 2015; 11():591-4. PubMed ID: 26648730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
    Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
    Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
    Ibrahim NK; Hortobagyi GN; Ewer M; Ali MK; Asmar L; Theriault RL; Fraschini G; Frye DK; Buzdar AU
    Cancer Chemother Pharmacol; 1999; 43(6):471-8. PubMed ID: 10321507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy.
    Sipola P; Vanninen E; Jantunen E; Nousiainen T; Kiviniemi M; Hartikainen J; Kuittinen T
    Nucl Med Commun; 2012 Jan; 33(1):51-9. PubMed ID: 22044862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy.
    Blaes AH; Gaillard P; Peterson BA; Yee D; Virnig B
    Breast Cancer Res Treat; 2010 Jul; 122(2):585-90. PubMed ID: 20058065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
    Alexander J; Dainiak N; Berger HJ; Goldman L; Johnstone D; Reduto L; Duffy T; Schwartz P; Gottschalk A; Zaret BL
    N Engl J Med; 1979 Feb; 300(6):278-83. PubMed ID: 759880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
    Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M
    J Clin Oncol; 1992 Jan; 10(1):117-27. PubMed ID: 1727913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radionuclide ejection fraction in doxorubicin cardiotoxicity.
    Morgan GW; McIlveen BM; Freedman A; Murray IP
    Cancer Treat Rep; 1981; 65(7-8):629-38. PubMed ID: 7248982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
    Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
    J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
    Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
    J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.